2-[4-(4-amino-2-chloro-phenyl)-piperazin-1-yl]-ethanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[4-(4-amino-2-chloro-phenyl)-piperazin-1-yl]-ethanol
• 英文别名: 2-[4-(4-amino-2-chlorophenyl)piperazin-1-yl]ethanol
• 化学式: C₁₂H₁₈ClN₃O
• mdl: MFCD08056118
• 分子量: 255.747
• InChiKey: WMXXTQAESAQMFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[6-[(2-Chloropyrimidin-4-yl)amino]-2,3-dimethylphenyl]acetonitrile 、 2-[4-(4-amino-2-chloro-phenyl)-piperazin-1-yl]-ethanol 在 三氟乙酸 作用下， 以 正丁醇 为溶剂， 反应 3.0h， 以9%的产率得到2-(6-(2-(3-chloro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)pyrimidin-4-ylamino)-2,3-dimethylphenyl)acetonitrile
  参考文献：
  名称：

  [EN] JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE
  [FR] INHIBITEURS DE JAK2 ET ALK2 ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2014151871A9

文献信息

• [EN] VEGFR TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE VEGFR
  申请人：SUZHOU VIVOTIDE BIOTECHNOLOGIES CO LTD

  公开号：WO2014183300A1

  公开（公告）日：2014-11-20

  Novel compounds, their prodrugs, and the pharmaceutically acceptable salts as pharmaceutical compositions containing such compounds useful in treating certain diseases modulated by the inhibition of vascular endothelial growth factors (VEGFs) receptor tyrosine kinases are provided. In particular, compounds and compositions and the methods for the prophylaxis, management and treatment of cancers through the inhibition of VEGF receptor tyrosine kinases are provided.

  提供了作为含有这些化合物的药物组合物的前药和药用盐，用于治疗受血管内皮生长因子（VEGFs）受体酪氨酸激酶抑制调节的特定疾病。具体提供了通过抑制VEGF受体酪氨酸激酶来预防、管理和治疗癌症的化合物、组合物和方法。
• JAK2 and ALK2 inhibitors and methods for their use
  申请人：Tolero Pharmaceuticals, Inc.

  公开号：US10202356B2

  公开（公告）日：2019-02-12

  Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明公开了具有 ALK2 激酶和/或 JAK2 激酶抑制剂活性的化合物。这些化合物具有以下结构 (I)： 其中 R1、R2、R3、R4、R5、R6、R7、R8、X、z 和 A 如本文所定义。此外，还公开了与制备和使用此类化合物相关的方法，以及包含此类化合物的药物组合物。
• JAK1 and ALK2 inhibitors and methods for their use
  申请人：Tolero Pharmaceuticals, Inc.

  公开号：US10752594B2

  公开（公告）日：2020-08-25

  Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明公开了具有 ALK2 激酶和/或 JAK2 激酶抑制剂活性的化合物。这些化合物具有以下结构 (I)： 其中 R1、R2、R3、R4、R5、R6、R7、R8、X、z 和 A 如本文所定义。此外，还公开了与制备和使用此类化合物相关的方法，以及包含此类化合物的药物组合物。
• JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE
  申请人：Tolero Pharmaceuticals, Inc.

  公开号：EP2970205B1

  公开（公告）日：2019-05-08